MT-TG
Chr MTtRNA-Gly
Also known as: MTTG
Moderate evidence — consider for supplementary testing
Population Genetics & Constraint
Constraint data not available from gnomAD.
ClinVar Variant Classifications
30 submitted variants in ClinVar
Classification Summary
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories· variant type breakdown unavailable
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | — | — | — | — | 0 |
Likely Pathogenic | — | — | — | — | 0 |
VUS | — | — | — | — | 14 |
Likely Benign | — | — | — | — | 6 |
Benign | — | — | — | — | 10 |
| Total | — | 30 | |||
Counts from ClinVar esearch · Updated hourly
View in ClinVar →17 pathogenic / likely-pathogenic (of 17) ClinVar copy-number / structural variants overlap MT-TG — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →
Protein Context — Lollipop Plot
MT-TG · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
NOT YET RECRUITINGA Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITINGTesting the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RECRUITINGExternal Resources
Links to major genomics databases and tools